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Ductal carcinoma in situ of the breast (DCIS) is viewed as a
precursor of invasive breast cancer. Approximately half of the
local recurrences after treatment for a primary DCIS are invasive
(Rosen et al, 1980; Page et al, 1982; Bradley et al, 1990; Price
et al, 1990; Graham et al, 1991; Swain, 1992; Fisher et al, 1993;
Solin et al, 1996). Autopsy studies, however, strongly suggest that
not all DCIS lesions progress to invasiveness during a patient’s
lifetime (Andersen et al, 1985). It would be relevant to be
cognizant of which lesions have a high risk of progression. The
genetic steps necessary for malignant transformation are not
known and we do not know if these are reflected in the presence or
absence of prognostic tumour markers. A substantial proportion of
small invasive carcinomas does not have detectable areas of in situ
carcinoma and possibly, in these, some crucial genetic changes
have occurred early in the process. Thus, it is likely that invasive
breast cancer can also occur de novo. 
We aimed to determine if the distribution of some commonly
used prognostic markers could help us to distinguish a group of
DCIS patients with a high probability of progression to invasive-
ness, or if any change in tumour markers between DCIS and inva-
sive lesions could yield interesting clues as to tumour biology. We
also studied the distribution of tumour markers relative to histopatho-
logical grade. Several studies have indicated that poorly differenti-
ated DCIS might be a precursor to poorly differentiated invasive
breast cancer and well-differentiated DCIS to well-differentiated
invasive breast cancer. Both histopathological grade and DNA
contents have been reported to be similar in the invasive and in the
in situ parts of mixed breast carcinomas (Iglehart et al, 1995;
Douglas-Jones et al, 1996; Gupta et al, 1997; Buerger et al, 1999). 
We studied the distribution of tumour markers in 3 cohorts of
women with breast carcinoma: pure DCIS, small invasive breast
carcinomas ≤ 10 mm and breast carcinomas that contained both an
in situ and an invasive element. We hypothesized that tumours
with both DCIS and an invasive component constituted a group in
which malignant transformation was underway. Further, we
assumed that small invasive carcinomas ≤ 10 mm without any
in situ component were a group in which only a small proportion
of the tumours had gone through a stage of DCIS before becoming
invasive. Women with pure DCIS served as a reference group in
which the crucial malignant transformation to invasiveness was
assumed not to have taken place. 
MATERIALS AND METHODS 
Patients 
We investigated 3 cohorts of women. 2 of the cohorts were
recruited from the catchment areas of Uppsala and Västerås hospi-
tals during the years 1986 to 1994. The first cohort contained all
DCIS reported to the Swedish Cancer Registry (SCR) from these
hospitals. This area is served by public health care and with no
other pathological departments than the 2 in Uppsala and Västerås.
75% of the DCIS (n = 145) were detected by mammography
screening 2 were detected ‘en passent’ while operated for other
reasons and the rest were detected clinically. After re-evaluation
of all histopathological slides, the cohort contained 194 women
with primary DCIS without any signs of invasive breast cancer.
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carcinoma with a diameter of 10 mm or less as stated by the orig-
inal pathological report, reported to the SCR from the same region.
In 12 cases, we did not find the original paraffin-embedded mate-
rial or tumour material to perform immunohistochemical (IH)
staining. After re-evaluation of the slides, the cohort contained
293 women who had lesions with an invasive breast carcinoma
≤ 10 mm without (n = 127) or with (n = 166) a DCIS component.
The latter group was included in the third cohort described below. 
The third cohort contained all women with an invasive breast
cancer diagnosed in Uppsala County between the years 1986 and
1995, where it was stated in the original pathological report that
the lesion had an in situ component. All cases were re-evaluated
and those with both a DCIS and an invasive breast carcinoma in
the same lesion were included. The mixed lesions with a diameter
of 10 mm or less during the period 1986 to 1994 were already re-
evaluated and recruited from the second cohort described above.
In 14 cases, we did not find any tumour material to make new
slides. 
Consequently, the final studied cohorts consisted of the
following cases: pure DCIS (n = 194), invasive cancer ≤ 10 mm
without an in situ component (n = 127) and lesions with both an
invasive and an in situ component (n = 305). 
Methods 
First, all histopathological specimens, routinely stained according
to van Gieson, were re-evaluated. A DCIS lesion was classified
according to the European Organisation for Research and
Treatment of Cancer (EORTC) classification system (Holland
et al, 1994). In this study we denoted the grades A–C (corre-
sponding to grades I–III) to make clear that in situ and invasive
lesions were classified based on different systems. If there was a
dominating histopathological pattern and only a small focus of
another pattern, we classified the lesion in accordance with the
dominating pattern. Otherwise, we classified the lesion based on
the lowest differentiated pattern in the lesions with a mixed DCIS
pattern. We defined a ‘small’ focus as being at maximum 25% of
the total tumour area. 
Invasive breast cancer was classified based on the Elston–Ellis
classification system, grades I–III (Elston and Ellis, 1991), and,
in lesions with both an invasive and an in situ element, the
classification was done in both parts separately according to the
Elston–Ellis or the EORTC classification system, respectively.
The extent of the in situ component was measured as more or less
than 25% of the diameter of the invasive cancer. Even if the inva-
sive part of a mixed lesion was very small (< 2 mm in diameter), it
was referred to as an invasive breast cancer. However, in accor-
dance with the Elston–Ellis system, no classification was possible
in these small invasive lesions. 
Second, new slides from the same tumour area that was
histopathologically studied were prepared for IH staining of
paraffin-embedded material for each tumour marker separately.
The results of the staining were analysed in the in situ and the
invasive components separately in all lesions with a mixed pattern.
Overexpression of the p53 protein was classified into 4 groups
according to the total percentage of positive tumour cells (0, 1–30,
31–60 and >60%). A cut-off limit for positive staining was chosen
at p53 > 0%, regardless of the intensity of the staining. We
assessed the membrane staining of the protein coded by the c-
erbB-2 oncogene in the same way, but it was classified into 5
different groups (0, 1–10, 11–30, 31–60 and >60%). The staining
for c-erbB-2 was considered positive when more than 30% of the
cells had a moderate or strong intensity of the membrane staining
or when more than 60% of the cell membranes were stained,
regardless of the intensity of the staining. The intensity of the
staining was classified subjectively as mild, moderate or strong.
Cell proliferation was measured with reference to the percentage
of tumour cells that stained for the nuclear protein Ki-67. We clas-
sified it into 5 different groups in the same way as we did with the
c-erbB-2 protein. A cut-off limit for positive staining was chosen
Ki-67 ≥ 10%, regardless of the intensity of the staining. 
We also stained for the hormone receptors for oestrogen (ER)
and progesterone (PR) and the protein coded by the bcl-2 gene; we
classified these slides based on the proportion of tumour cells
stained (0–100%). We also classified the intensity of the staining
as mild, moderate or strong for all different factors. Cut-off
limits for positive staining was chosen ER ≥ 10%, PR ≥ 10% and
bcl-2 ≥ 10%, irrespective of the intensity of the staining. 
The antibody CD 31 (or JC 70) that stains for endothelial cells
was used to study angiogenesis. We used a grading system for
invasive breast cancer, where we graded the number of microves-
sels into 3 categories: low/normal, medium and high compared
with the number of microvessels in the normal parenchyma. It was
a subjective evaluation performed with a light microscope in a 200
× field by our breast pathologist (HN). No hot spots were used and
we looked both at the tumour and at the surrounding tissue. In the
pure DCIS lesions and in the in situ part of the mixed lesions the
angiogenesis was graded as normal or high in the stroma between
the ducts. The amount of vessels in the stroma between normal
breast ducts was used as a reference in each case. We also noted if
there was a dense rim of microvessels adjacent to the basement
membrane of DCIS ducts (cuffing phenomenon) as earlier
described by Guidi and by Engels (Guidi et al, 1994; Engels et al,
1997). The cuffing phenomenon was scored as present (defined as
microvessels completely surrounding one involved duct or
surrounding at least 50% of 2 or more involved ducts) or absent. 
The antibodies used were p53 clone DO-7, DAKO, c-erbB-2
poly rabbit, DAKO, Ki-67 MIB-1, Immunotech, KEBO, ER 6F11,
Novocastra, PR 1A6, Novocastra, Bcl-2 clone 124, DAKO and
CD31 clone JC/70A, DAKO. The staining was performed in an
automatic staining machine (Ventana Medical Systems, Inc). 
This study was approved by the Ethics Committee at Uppsala
University Hospital. 
Statistical methods 
For comparison of proportions between the groups, the chi-square
test was used and differences between 2 means were assessed with
Student’s t-test for unpaired data. Statistically significant differ-
ences were assumed when P < 0.05. The association between the
staining of the different tumour markers in the DCIS and the inva-
sive components of mixed lesions was described as the proportion
of lesions in which both parts stained positive or both parts stained
negative. The statistical trend of staining by histopathological
tumour grades A–C or I–III for the different tumour markers in
invasive and in situ carcinomas, respectively, was calculated with
logistic regression models that used grade as an ordinal variable
and estimated odd ratios with 95% confidence interval. The
Microsoft Statistica and SAS software were used for all statistical
calculations. 
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Among the 626 women included in this study we could not find
paraffin-embedded material in 30 cases (5%). These women were
included in analyses using the van Gieson staining technique only.
In another 46 (7%) cases one or more of the IH staining was not
performed, mainly due to a small tumour size that did not allow us
to prepare all slides needed. 
The mean age in the different cohorts was 60.0 years in women
with pure DCIS, 60.0 years in women with invasive breast carci-
noma ≤ 10 mm without an in situ component and 59.0 years in
women with lesions with both an invasive and an in situ compo-
nent. When we calculated the mean size of the lesions in the
different cohorts, we only included lesions described in mm in the
original pathological report. The mean size was 14.9 mm in
women with pure DCIS (n = 120), 8.0 mm in women with invasive
breast carcinoma ≤ 10 mm without an in situ component (n = 127).
In the cohort with mixed lesions the subgroup of lesions ≤ 10 mm
had a mean size of 7.8 mm (n = 172) and the subgroup with larger
lesions had a mean size of 23.9 mm (n = 90). In the group with
mixed lesions only the invasive component of the lesion was
measured, and the in situ part was described as more or less than
25% of the invasive component. 
The proportions of lesions showing positive staining for the
different tumour markers and the distribution of lesions according
to histopathological grade in the different cohorts are summarised
in Table 1. Overexpression of both p53 and c-erbB-2 protein was
more frequently seen in the pure DCIS lesions than in the invasive
lesions, both with and without an in situ component. The differ-
ence was statistically significant when we compared DCIS with all
invasive lesions together (P53, P < 0.001 and c-erbB-2, P < 0.05).
Proliferation, measured with Ki-67 staining, was less frequent in
the pure DCIS group, but this difference was not statistically
significant. Although the proportions of positive-stained tumour
cells for ER, PR and bcl-2 were lower in pure DCIS compared
with the invasive lesions, the difference failed to reach statistical
significance. Because angiogenesis was classified in different
ways, it was not possible to compare the proportion of positive
staining between pure DCIS and invasive carcinomas. 
The DCIS and the invasive carcinomas were graded using
different histopathological systems. As shown in Table 1, in pure
DCIS there were few well-differentiated lesions (i.e., grade A) and
a large proportion of poorly differentiated lesions (i.e., grade C). In
the small invasive tumours, without an in situ component, about
50% were grade I while only 4.9% were grade III. In the mixed
lesions over 50% were grade I and 8.3% were grade III. In the
cohort with mixed lesions the larger tumours (> 10 mm) were
more often poorly differentiated (grade III) than the smaller
tumours (P < 0.001). 
An unexpected finding was the more ‘malignant picture’ in the
DCIS cohort compared with the invasive tumours. Because the
distribution of grade was materially different in the cohorts and
because grade might be a stronger marker for tumour progression
in comparison with any of the other tumour markers we stained
for, we analysed the staining for the tumour markers by grade.
These results are presented in Table 2. 
Based on tumour grade, almost every biological event that the
different staining represented had a statistically significant trend of
a more ‘malignant picture’ in both the in situ and the invasive
cohorts (Table 2). The frequency of p53 and c-erbB-2 was highest
in grade C and grade III lesions in all cohorts. Further, prolifera-
tion was more pronounced in poorly differentiated lesions. A
higher proliferation was seen in the invasive cohorts than in pure
DCIS when we compared each grade separately (A vs. I, B vs. II
and C vs. III). This difference was statistically significant between
grade B and grade II (9% vs. 34%, P < 0.001) and between grade
C and grade III (33% vs. 56%, P < 0.05). 
Poorly differentiated lesions were found to stain less for
hormone receptors and bcl-2 than well-differentiated tumours in
all cohorts. When we compared each grade individually, the pure
DCIS lesions exhibited a higher percentage of staining than the
invasive lesions (A vs. I, B vs. II and C vs. III). The poorly differ-
entiated lesions displayed the most pronounced angiogenesis in all
cohorts. Moreover, in pure DCIS lesions the cuffing phenomenon
of microvessels was more common in grade C lesions as compared
with grades A and B lesions (P < 0.01) (Table 2). 
We looked at the in situ component of the mixed lesions and the
same pattern of a more ‘malignant picture’ was noted according to
grade (Table 2). The correlation between the DCIS component and
the invasive part of the mixed lesions, based on the staining for the
different tumour markers, is displayed in Table 3. The staining of
the invasive and in situ components was highly correlated for all
Tumour biology in invasive and in situ carcinoma of the breast 871
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Table 1 The percentage of women indicating positive staining for different tumour markers and the percentage and number of women according to
histopathological grade by subgroup. DCIS was classified in accordance with the EORTC system (grades A–C) and invasive breast carcinoma according to the
Elston–Ellis system (grades I–III). Cut-off limits are given in the text
Invasive breast carcinoma ≤ 10 mm without an Invasive breast carcinoma with
DCIS pure in situ component an in situ component 
(n = 194) (n = 127) (n = 305) 
P53 40% 25% 28% 
C-erbB-2 55% 41% 49% 
Ki 67 19% 21% 27% 
ER + 68% 78% 71% 
PR + 43% 52% 52% 
Bcl2+ 48% 52% 57% 
CD31 
Stroma 35% 27% 35% 
Cuffing 23% ––  
Grade A-I 6.7% (13) 51.2% (63) 56.3% (156) 
Grade B-II 50.5% (98) 43.9% (54) 35.4% (98) 
Grade C-III 42.8% (83) 4.9% (6) 8.3% (23) 
BJOC 01-1995 869-874  10/9/01  1:55 pm  Page 871tumour markers in both small and large mixed tumours. The distri-
bution of histopathological grade in the in situ component of the
mixed lesions was more like the distribution of histopathological
grade in the lesions with pure DCIS than in the corresponding
invasive components. 
The correlation between the histopathological grade in the
DCIS and the invasive components of mixed lesions is depicted
in Table 4. In 10 of the 144 invasive tumours (7%), classified as
grade I, the DCIS component was classified as grade C. Only one
of the 24 invasive tumours (4%), classified as grade III, was corre-
lated with a grade A or grade B DCIS. 
We also studied the pattern of the tumour markers in all mixed
lesions based on whether the extent of the in situ component was
greater or smaller than 25% of the diameter of the corresponding
invasive component. No statistically significant differences were
seen between these 2 patterns. 
DISCUSSION 
We constructed a semi-experimental setting to observe whether
there were any marked differences in the distribution of tumour
markers between in situ and invasive lesions. We could not detect
any pattern that signalled the progression from an in situ stage to
invasiveness. Instead, the main finding was that the expression
of the different tumour markers strongly correlated with tumour
grade in both DCIS and invasive breast cancer. 
We studied a large number of tumours in well-defined
subgroups. A high proportion of tumours could be IH stained with
few losses because of missing tumour material. We do not know
how different fixation and storage of the tumours may have influ-
enced the results. However, we recruited the tumours from the
same pathological departments and from the same time period and
we have no reason to believe that the technical difficulties would
be different between in situ and invasive components. Thus,
comparisons between the cohorts should be valid though any 
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Table 3 The correlation of the staining of different tumour markers between the invasive and the in situ part in mixed breast carcinomas. The percentage of
lesions with either both parts positive or both parts negative (++/––) are given. The numbers of lesions, invasive part and in situ part respectively, with positive
(+), negative (–) staining or where staining was not performed (np) are given. Cut-off limits are given in the text
P53 C-erb-B2 Ki 67 ER PR Bcl2 CD 31 stroma 
Invasive breast carcinoma ≤ 10 
mm with in situ, ++/–– 80% 93% 89% 91% 82% 91% 75% 
Invasive part + / – / np 46/115/15 74/90/12 41/123/12 121/26/29 78/66/32 82/66/28 39/119/18 
In situ part + / – / np 26/127/23 80/87/9 40/118/18 120/22/34 86/51/39 79/63/34 45/103/28 
Invasive breast carcinoma 
> 10 mm with in situ ++ / –– 93% 93% 91% 96% 87% 86% 73% 
Invasive part + / – / np 30/84/15 63/55/11 35/83/11 63/50/16 54/57/18 67/47/15 53/55/21 
In situ part + / – / np 34/79/16 67/52/10 34/84/11 67/47/15 59/53/17 68/46/15 46/66/17 
Table 4 The correlation between the in situ and the invasive parts of mixed
lesions based on the histopathological grade. Numbers are given. DCIS was
classified according to the EORTC system (grades A–C) and invasive breast
carcinoma according to the Elston–Ellis system (grades I–III)
Lesions with both a DCIS 
and an invasive component Invasive component 
Grade I Grade II Grade III 
DCIS component
Grade A 40 5 0 
Grade B 94 39 1 
Grade C 10 47 23 
Table 2 The percentage of women with a positive staining for different tumour markers as a function of subgroup and grade. The number and percentage of
women according to histopathological grade are given for the different parts in the mixed lesions. DCIS was classified according to the EORTC system (grades
A–C) and invasive breast carcinoma according to the Elston–Ellis system (grades I–III). Cut-off limits are given in the text
DCIS pure Invasive breast carcinoma  Invasive breast carcinoma
≤ 10 mm without an in situ  (I–III) with an in situ
component component (A–C) 
Grade A B C I II III I II III A B C 
56.3% 35.4% 8.3% 18.1% 51.3% 30.6% 
(n = 156) (n = 98) (n = 23) (n = 49) (n = 139) (n = 83) 
P53 0% 25% 63%* 13% 21% 67%* 17% 33% 71%* 4% 15% 47%*
C-erbB-2 31% 27% 75%* 35% 33% 83% 43% 53% 70%* 30% 49% 73%*
Ki 67 0% 9% 33%* 5% 23% 67%* 15% 41% 52%* 12% 22% 46%*
ER + 92% 85% 46%* 81% 71% 17%* 77% 70% 30%* 81% 78% 57%*
PR + 83% 54% 25%* 46% 46% 0% 57% 56% 21%* 55% 69% 41% 
BCl2+ 83% 54% 37%* 54% 41% 33% 66% 48% 37%* 70% 65% 40%*
CD31 
Stroma 25% 22% 52%* 13% 40% 100%* 25% 42% 68% 13% 29% 56%*
Cuffing 8% 12% 31%* –– – – – – 0% 6% 21%*
*Statistically significant trend of the staining for the tumour markers according to grade in the different groups. 
BJOC 01-1995 869-874  10/9/01  1:55 pm  Page 872non-differential misclassification may lower the power to detect
small or moderate differences. 
The cohort with pure DCIS showed a more ‘malignant pattern’
regarding all tumour markers, except for proliferation. Similar to
other studies, the overexpression of c-erb-B2 in DCIS was most
frequently seen in poorly differentiated lesions. C-erbB-2 over-
expression was also more frequently found in the cohort with pure
DCIS compared with invasive lesions (Allred et al, 1992;
Somerville et al, 1992; Leal et al, 1995), but if we compared each
grade separately it was more common in invasive carcinomas (A/I,
B/II and C/III). Contrary to Allred’s (Allred et al, 1992) sugges-
tion, the present results do not support the hypothesis that overex-
pression of c-erbB-2 decreases within individual tumours as they
evolve from in situ to invasive carcinomas. As in our study,
Igelhart et al found that the expression of c-erbB-2 was similar in
both growth phases of lesions with an invasive and an in situ
component (Iglehart et al, 1995). 
The quantification of angiogenesis in breast cancer is a
prevailing topic (Fox et al, 1995) and there is no standard method
used for both DCIS and invasive breast cancer. In this study we
used a semi-quantitative method and then classified the amount of
microvessels as high or low. The angiogenesis in DCIS and inva-
sive carcinomas was not classified in exactly the same way.
However, we did compare the angiogenesis by grade in the
different cohorts separately. When we compared the angiogenesis
in the 2 growth stages of the mixed lesions, DCIS and invasive
carcinoma, we found a statistically significant correlation between
the components though not as strong as among the other tumour
markers. 
We used 2 histopathological classification systems for DCIS
and invasive carcinomas since there is no single system dealing
with both entities. In the mixed lesions the grade of the 2 compo-
nents, in situ and invasive carcinoma, was basically but not totally
corresponding (Table 4). When we studied the expression of the
different tumour markers, however, the expression of the markers
in the 2 components was almost identical (Table 3). These findings
support the theory that a well-differentiated DCIS progresses to a
well-differentiated invasive cancer and a poorly differentiated
DCIS progresses to a poorly differentiated invasive cancer.
Consequently, it is probable that the step between invasive and
in situ carcinoma occurs independently of tumour grade. 
The distribution of lesions by grade in pure DCIS and small
invasive lesions (≤ 10 mm) (Table 1) showed a small proportion
of well-differentiated DCIS and, on the contrary, a large propor-
tion of well-differentiated small invasive carcinomas. One expla-
nation of the different distributions of pure DCIS by grade
compared with small invasive carcinomas can be that poorly
differentiated DCIS with calcifications is more easily detected by
mammography than DCIS without calcifications (Stomper et al,
1989). 75% of the DCIS were screening detected in this study.
However, the difference in distribution by grade between pure
DCIS and small invasive lesions may also be artificial in that we
used different histopathological classification systems in the 2
groups. The DCIS and the invasive parts of mixed lesions
appeared very similar regarding the staining of all tumour markers.
However, if we classified the DCIS component of the mixed
lesions based on the EORTC classification system and looked at
the pattern of the staining for the tumour markers by grades A–C,
the pattern shifted towards the pattern of the cohort with pure
DCIS (Table 2). Furthermore, the distribution by grade was more
comparable to that of the cohort with pure DCIS. This distribution
pattern may indicate that histopathological grades A–C and grades
I–III are not exchangeable or do not represent the same level of
biological differentiation. 
Grade is prognostically important within the in situ and invasive
groups. The other biological markers we studied – reflecting more
of singular entities than grade – are all strongly correlated with
grade. In in situ carcinomas high grade entails a higher risk of local
new events (of which 50% are invasive); in invasive carcinomas
high grade is also associated with risk of distant metastases. It is
intriguing that patterns of grade or the other markers did not seem
to mark the transition from in situ to invasive carcinoma, a step
believed to be crucial for the tumour’s ability to metastasise. We
postulate that factors that signal the tumour’s ability to invade may
be powerful prognostic factors and that they may be searched for
in a setting comparable to ours. 
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